What is tremelimumab?

Tremelimumab, sold under the trade name Imjudo after its launch, is a fully human monoclonal antibody mainly used to treat hepatocellular carcinoma (uHCC). It is also often combined with durvalumab. Temtumumab is designed to attach to and block CTLA-4, a protein that controls the activity of T cells, which are part of the immune system, the body's natural defense system.

Ticilimumab, originally known as ticilimumab in English, is a fully human IgG2 monoclonal antibody targeting cytotoxicT lymphocyte-associated antigen 4 (CTLA-4). CTLA-4 is a cell surface receptor expressed on activated T cells and serves as a negative regulator of T cells. By binding to CTLA-4, temsitumumab enhances T cell-mediated tumor killing and reduces tumor growth. But Since CTLA-4 is an immune checkpoint and plays an important role in regulating T cell-mediated immune responses, temtumumab is also regarded as an immune checkpoint inhibitor. The most common side effects of temsitumumab include rash, pruritus, diarrhea, abdominal pain, fever, hypothyroidism, cough, peripheral edema, and elevated lipase levels.

Tesetumumab is an emerging cancer immunotherapy drug that has not yet been launched in China, so it has not been included in the medical insurance. Domestic patients cannot yet purchase this drug. The U.S. version of temsitumumab’s original drug has been on the market overseas for a short time, and the price is not yet clear. There is currently no known generic version of temsitumumab that has been produced and launched. For specific prices and drug details, please consult Yaode’s medical consultant.